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To the editor: 
 The study of physiological changes during spaceflight, and the pursuit of 
remedies to counteract those changes, often requires unique research protocols that 
lead to unexpected findings; some with important clinical implications.  In our research 
into the development of treatments to counteract the detrimental cardiovascular effects 
of spaceflight, we have discovered an important drug interaction between 
promethazine and midodrine.   
 Promethazine has been the antiemetic of choice by NASA flight surgeons for 
about 15 years for the treatment of postflight nausea and vomiting .  This laboratory 
has long pursued a pharmacological countermeasure for postflight orthostatic 
hypotension.  We chose to evaluate midodrine because it is fast-acting, and has no 
cardiac or central side effects (4).  Because midodrine and promethazine would likely 
be used together on landing day, we designed a study to determine if promethazine 
would counteract the positive effects of midodrine on orthostatic tolerance.   
Methods 
 Ten healthy subjects gave written, informed consent to participate in this 
protocol, which was approved by the Johnson Space Center Committee for the 
Protection of Human Subjects; one subject withdrew from the study.  The remaining 
subjects received all of four treatments, in random order (numbers 1-4 drawn from hat), 
separated by at least four days, with all combinations of 10 mg oral midodrine, 25 mg 
intravenous promethazine (infused over 12 minutes) and appropriate placebos 
(identical in appearance to test drugs).  No subject had received any other medication 
within 24 hours prior to any testing.  We discovered a profound akathisia when 
midodrine and promethazine were given together and quantified severity with the 
Barnes global akathisia score. (2).  Data were normally distributed, and had equal 
variance.  Treatments were compared using repeated measures ANOVA with a 
Bonferroni ad hoc test..SigmaStat© software was used.  Significance was set at p ≤ 
0.05.  The tilt tolerance data will be reported separately. 
 
Results 
Akathisia was experienced by: no subject with placebo alone; no subject with 
midodrine alone: four subjects with promethazine alone; and 6 subjects with midodrine 
and promethazine together. In addition, the severity of akathisia, measured by the 
Barnes global akathisia rating, was significantly greater (p=0.047) with midodrine and 
promethazine together (2.0±0.6 SEM) than with promethazine alone (0.8±0.4 SEM).     
  
Comments 
 The fact that promethazine and midodrine together produced such profound 
akathisia in a majority of our subjects was unexpected.  While, it is well known that 
phenothiazines (including promethazine) tend to induce akathisia (3), there have been 
no report that midodrine induces akathisia.  However, both drugs are metabolized by 
the cytochrome P450 isozyme CYP2D6 (1, 6).  One could expect that promethazine, 
given in the presence of midodrine, would have increased bioavailability and 
decreased clearance.  The highly polymorphic nature of this enzyme in the population 
would also suggest that poorer metabolizers would be more susceptible to this kinetic 
interaction (6).  Since its approval by the FDA, midodrine has become a first line 
treatment for patients with orthostatic hypotension due to various autonomic 
neuropathies (5).  Physicians who encounter these patients, particularly in acute 
settings, should be aware of this drug interaction and take careful histories regarding 
midodrine therapy before prescribing promethazine, or any other drug metabolized by 
CYP2D6  NASA has already taken the step of prohibiting the use of these two drugs 
together.   
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